Results of a reevaluation of cardiovascular outcomes in the RECORD trial

被引:137
|
作者
Mahaffey, Kenneth W. [1 ]
Hafley, Gail [1 ]
Dickerson, Sheila [1 ]
Burns, Shana [1 ]
Tourt-Uhlig, Sandra [1 ]
White, Jennifer [1 ]
Newby, L. Kristin [1 ]
Komajda, Michel [2 ,3 ]
McMurray, John [4 ]
Bigelow, Robert [1 ]
Home, Philip D. [5 ]
Lopes, Renato D. [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[2] Univ Paris 06, Paris, France
[3] Hop La Pitie Salpetriere, Paris, France
[4] Univ Glasgow, Glasgow, Lanark, Scotland
[5] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
关键词
INFARCTION END-POINTS; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; PRIMARY PREVENTION; CARDIAC OUTCOMES; CLINICAL-TRIAL; TYPE-2; ROSIGLITAZONE; DISEASE; EVENTS;
D O I
10.1016/j.ahj.2013.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The US Food and Drug Administration (FDA) required a reevaluation of cardiovascular (CV) outcomes in the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as well as to use new FDA end point definitions in development. Methods Original data were used to systematically identify all potential deaths, myocardial infarctions (MIs), and strokes. Site investigators were approached for additional source documents and information about participants lost to follow-up. Suspected events were adjudicated using standard procedures, and the results were compared with the original trial outcomes. Results Follow-up for mortality was 25,833 person-years, including an additional 328 person-years identified during the reevaluation effort. A total of 184 CV or unknown-cause deaths (88 rosiglitazone, 96 metformin/sulfonylurea), 128 participants with an MI (68 rosiglitazone, 60 metformin/sulfonylurea), and 113 participants with a stroke (50 rosiglitazone, 63 metformin/sulfonylurea) were included. The hazard ratio (HR) for rosiglitazone versus metformin/sulfonylurea for the end point of CV (or unknown cause) death, MI, or stroke was 0.95 (95% CI 0.78-1.17) compared with 0.93 (95% CI 0.74-1.15) for the original RECORD results. Treatment comparisons for MI (HR 1.13, 95% CI 0.80-1.59) and mortality (HR 0.86, 95% CI 0.68-1.08) were also the same compared with the original RECORD results. Sensitivity analyses were also consistent with the original RECORD results. Analyses using the FDA definitions showed similar results. Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.
引用
收藏
页码:240 / +
页数:11
相关论文
共 50 条
  • [1] Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
    Lopes, Renato D.
    Dickerson, Sheila
    Hafley, Gail
    Burns, Shana
    Tourt-Uhlig, Sandra
    White, Jennifer
    Newby, L. Kristin
    Komajda, Michel
    McMurray, John
    Bigelow, Robert
    Home, Philip D.
    Mahaffey, Kenneth W.
    AMERICAN HEART JOURNAL, 2013, 166 (02) : 208 - +
  • [2] Canakinumab and cardiovascular outcomes: results of the CANTOS trial
    Shah, Syed Raza
    Abbasi, Zainab
    Fatima, Mazia
    Ochani, Rohan Kumar
    Shahnawaz, Waqas
    Khan, Muhammad Asim
    Shah, Syed Arbab
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2018, 8 (01): : 21 - 22
  • [3] Rosiglitazone Evaluated for Cardiovascular Outcomes: An Interim Analysis of the RECORD Trial
    Kurukulasuriya, L. Romayne
    McFarlane, Samy I.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2008, 2 (02) : 85 - 87
  • [4] Rosiglitazone evaluated for cardiovascular outcomes: An interim analysis of the RECORD trial
    L. Romayne Kurukulasuriya
    Samy I. McFarlane
    Current Cardiovascular Risk Reports, 2008, 2 (2) : 85 - 87
  • [5] Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial
    Caterson, I. D.
    Finer, N.
    Coutinho, W.
    Van Gaal, L. F.
    Maggioni, A. P.
    Torp-Pedersen, C.
    Sharma, A. M.
    Legler, U. F.
    Shepherd, G. M.
    Rode, R. A.
    Perdok, R. J.
    Renz, C. L.
    James, W. P. T.
    DIABETES OBESITY & METABOLISM, 2012, 14 (06): : 523 - 530
  • [6] Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2020, 132 (04) : 314 - 319
  • [7] Triglyceride Variability and Risk of Adverse Cardiovascular Outcomes-Results from the ACCORD Trial
    Nuyujukian, Daniel S.
    Zhou, Jin
    Koska, Juraj
    Reaven, Peter
    DIABETES, 2023, 72
  • [8] Rosiglitazone evaluated for cardiovascular outcomes (RECORD) - An interim analysis
    Murphy, Sabina A.
    Gibson, C. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (06) : CS7 - CS8
  • [9] The COLchicine Cardiovascular Outcomes Trial (COLCOT)
    Tardif, Jean-Claude
    Kouz, Simon
    Waters, David D.
    Diaz, Rafael
    Maggioni, Aldo P.
    Pinto, Fausto J.
    Gamra, Habib
    Kiwan, Ghassan S.
    Berry, Colin
    Lopez-Sendon, Jose Luis
    Ibrahim, Reda
    Koenig, Wolfgang
    Ostadal, Petr
    Gregoire, Jean C.
    Provencher, Mylene
    Cossette, Marieve
    Nozza, Anna
    Blondeau, Lucie
    L'Allier, Philippe L.
    Guertin, Marie-Claude
    Roubille, Francois
    CIRCULATION, 2019, 140 (25) : E966 - E966
  • [10] The fragility of cardiovascular clinical trial results
    Moyé, LA
    Deswal, A
    JOURNAL OF CARDIAC FAILURE, 2002, 8 (04) : 247 - 253